Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 6/20 | 0.89 |
| ▸ | CDK2 | P24941 | 6/20 | 0.89 |
| ▸ | CDK7 | P50613 | 6/20 | 0.89 |
| ▸ | CCNH | P51946 | 4/20 | 0.89 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.89 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.89 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.89 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.89 |
| ▸ | CCNK | O75909 | 2/20 | 0.89 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.89 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.52 |
| ▸ | CDK1 | P06493 | 4/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.52 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25736240 | 0.95 | CDK9 (0.80) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL20550154 | 0.94 | CDK9 (1.00) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL18113959 | 0.94 | CDK9 (1.00) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL18122697 | 0.94 | CDK9 (1.00) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL25737155 | 0.92 | CDK9 (0.75) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL18122654 | 0.91 | CDK9 (0.87) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL20549699 | 0.91 | CDK9 (0.87) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL18113958 | 0.89 | CDK9 (0.70) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL20288859 | 0.88 | CDK9 (0.87) | CDK9CDK2CDK7CCNHCDK12 | |
| SCHEMBL20286065 | 0.88 | CDK9 (0.87) | CDK9CDK2CDK7CCNHCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50776-E1 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12098154-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3273966-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA FARBER CANCER INST INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3273966-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA FARBER CANCER INST INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220242865-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180319801-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK7 12/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | CDK9 89/4885CDK2 63/4885CDK7 130/4885 |
| US-20220242865-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK7 12/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | CDK9 89/4885CDK2 63/4885CDK7 130/4885 |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK7 12/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | CDK9 89/4885CDK2 63/4885CDK7 130/4885 |
| US-20180319801-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK7 12/4885 |
| US-12098154-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK7 12/4885 |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | CDK7, CDC7, CDK8 | CDK9 5/4885CDK2 17/4885CDK7 1/4885 |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK7 12/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK7 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.